NCT05063916View on ClinicalTrials.gov

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

February 28, 2022

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2027

Conditions

CarcinomasCervix CancerCervical Cancer

Interventions

DRUG

AK104

Given By IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER